Brokers Set Expectations for VIGL FY2029 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Vigil Neuroscience in a research report issued to clients and investors on Thursday, March 13th. Wedbush analyst L. Chico expects that the company will earn $1.40 per share for the year. Wedbush has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

A number of other analysts have also recently commented on the stock. William Blair assumed coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating for the company. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, HC Wainwright cut their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Price Performance

Shares of VIGL stock opened at $1.97 on Monday. The stock has a market cap of $80.53 million, a P/E ratio of -0.96 and a beta of 1.82. The company has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.76. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

Several large investors have recently modified their holdings of VIGL. Walleye Capital LLC raised its position in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the period. Verition Fund Management LLC bought a new position in shares of Vigil Neuroscience in the third quarter valued at about $442,000. Point72 Asset Management L.P. raised its position in shares of Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after purchasing an additional 115,000 shares during the period. Geode Capital Management LLC raised its position in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after purchasing an additional 66,712 shares during the period. Finally, abrdn plc raised its position in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after purchasing an additional 293,461 shares during the period. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.